Discovery of Imidazo[1,2-a]pyridine Ethers and Squaramides as Selective and Potent Inhibitors of Mycobacterial Adenosine Triphosphate (ATP) Synthesis

Journal of Medicinal Chemistry

Volumn 60, Issue 4, 2017, Pages 1379-1399

  Tantry, Subramanyam J ^a   Markad, Shankar D ^a   Shinde, Vikas ^a   Bhat, Jyothi ^a   Balakrishnan, Gayathri ^a   Gupta, Amit K ^a   Ambady, Anisha ^a   Raichurkar, Anandkumar ^a   Kedari, Chaitanyakumar ^a   Sharma, Sreevalli ^a   Mudugal, Naina V ^a   Narayan, Ashwini ^a   Naveen Kumar, C N ^a   Nanduri, Robert ^a   Bharath, Sowmya ^a   Reddy, Jitendar ^a   Panduga, Vijender ^a   Prabhakar, K R ^a   Kandaswamy, Karthikeyan ^a   Saralaya, Ramanatha ^a   Kaur, Parvinder ^a   Dinesh, Neela ^a   Guptha, Supreeth ^a   Rich, Kirsty ^a   Murray, David ^a   Plant, Helen ^a   Preston, Marian ^a   Ashton, Helen ^a   Plant, Darren ^a   Walsh, Jarrod ^a   Alcock, Peter ^a   Naylor, Kathryn ^a   Collier, Matthew ^a   Whiteaker, James ^a   McLaughlin, Robert E ^a   Mallya, Meenakshi ^a   Panda, Manoranjan ^a   Rudrapatna, Suresh ^a   Ramachandran, Vasanthi ^a   Shandil, Radha ^a   Sambandamurthy, Vasan K ^a   Mdluli, Khisi ^b   Cooper, Christopher B ^b   Rubin, Harvey ^c   Yano, Takahiro ^c   Iyer, Pravin ^a   Narayanan, Shridhar ^a   Kavanagh, Stefan ^a   Mukherjee, Kakoli ^a   Balasubramanian, V ^a   Hosagrahara, Vinayak P ^a   Solapure, Suresh ^a   Ravishankar, Sudha ^a   Hameed P, Shahul ^a   more..

^a ASTRAZENECA   (United Kingdom)

^b GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; BEDAQUILINE; CYTOCHROME C OXIDASE; ENZYME INHIBITOR; IMIDAZO[1,2 A]PYRIDINE ETHER DERIVATIVE; SQUARAMIDE DERIVATIVE; UNCLASSIFIED DRUG; ETHER DERIVATIVE; PYRIDINE DERIVATIVE; QUININE; SQUARAMIDE; TUBERCULOSTATIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME SYNTHESIS; IC50; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; STRUCTURE ACTIVITY RELATION; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DRUG EFFECTS; HUMAN; METABOLISM; MOLECULAR MODEL; TUBERCULOSIS;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTITUBERCULAR AGENTS; ETHERS; HUMANS; MICE; MICE, INBRED BALB C; MODELS, MOLECULAR; MYCOBACTERIUM TUBERCULOSIS; PYRIDINES; QUININE; TUBERCULOSIS;

EID: 85013754936     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.6b01358     Document Type: Article

References (51)

1. Global Tuberculosis Report 2015, 20th ed.; World Health Organization: Geneva, 2015; http://apps.who.int/iris/bitstream/10665/191102/1/9789241565059_eng.pdf (accessed Oct 7, 2015).
2. Dye, C.; Williams, B. G. The population dynamics and control of tuberculosis Science 2010, 328, 856-861 10.1126/science.1185449
3. Zumla, A.; Raviglione, M.; Hafner, R.; Fordham von Reyn, C. Tuberculosis N. Engl. J. Med. 2013, 368, 745-755 10.1056/NEJMra1200894
4. Gandhi, N. R.; Nunn, P.; Dheda, K.; Schaaf, H. S.; Zignol, M.; van Soolingen, D.; Jensen, P.; Bayona, J. Multidrug-resistant and extensively drug-resistant tuberculosis: A threat to global control of tuberculosis Lancet 2010, 375, 1830-1843 10.1016/S0140-6736(10)60410-2
5. Mandavilli, A. Virtually incurable TB warns of impending disaster Nat. Med. 2007, 13, 271-271 10.1038/nm0307-271a
6. Multidrug and Extensively Drug-Resistant TB (M/XDR-TB): 2010 Global Report on Surveillance and Response; World Health Organization, Geneva, 2010; http://www.who.int/tb/features_archive/m_xdrtb_facts/en/.
7. Mitchison, D. A. The diagnosis and therapy of tuberculosis during the past 100 years Am. J. Respir. Crit. Care Med. 2005, 171, 699-706 10.1164/rccm.200411-1603OE
8. Tsara, S.; Serasli, E.; Christaki, P. Problems in diagnosis and treatment of tuberculosis infection Hippokratia 2009, 13, 20-22
9. Russell, D. G.; Barry, C. E., III; Flynn, J. L. Tuberculosis: What we don’t know can, and does, hurt us Science 2010, 328, 852-856 10.1126/science.1184784
10. Horsburgh, C. R., Jr.; Barry, C. E., III; Lange, C. Treatment of tuberculosis N. Engl. J. Med. 2015, 373, 2149-2160 10.1056/NEJMra1413919
11. Koul, A.; Arnoult, E.; Lounis, N.; Guillemont, J. E. G.; Andries, K. The challenge of new drug discovery for tuberculosis Nature 2011, 469, 483-490 10.1038/nature09657
12. Check, E. After decades of drought, new drug possibilities flood TB pipeline Nat. Med. 2007, 13, 266-266 10.1038/nm0307-266
13. Dye, C. Doomsday postponed? Preventing and reversing epidemics of drug-resistant tuberculosis Nat. Rev. Microbiol. 2009, 7, 81-87 10.1038/nrmicro2048
14. Zumla, A.; Nahid, P.; Cole, S. T. Advances in the development of new tuberculosis drugs and treatment regimens Nat. Rev. Drug Discovery 2013, 12, 388-404 10.1038/nrd4001
15. Lienhardt, C.; Vernon, A.; Raviglione, M. C. New drugs and new regimens for the treatment of tuberculosis: Review of the drug development pipeline and implications for national programmes Curr. Opin. Pulm. Med. 2010, 16, 186-193 10.1097/MCP.0b013e328337580c
16. Silver, L. L. Challenges of antibacterial discovery Clin. Microbiol. Rev. 2011, 24, 71-109 10.1128/CMR.00030-10
17. Andries, K.; Verhasselt, P.; Guillemont, J. E. G.; Göhlmann, H. W. H.; Neefs, J. M.; Winkler, H.; van Gestel, J.; Timmerman, P.; Zhu, M.; Lee, E.; Williams, P.; de Chaffoy, D.; Huitric, E.; Hoffner, S. E.; Cambau, E.; Truffot-Pernot, C.; Lounis, N.; Jarlier, V. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis Science 2005, 307, 223-227 10.1126/science.1106753
18. Haagsma, A. C.; Abdillahi-Ibrahim, R.; Wagner, M. J.; Krab, K.; Vergauwen, K.; Guillemont, J.; Andries, K.; Lill, H.; Koul, A.; Bald, D. Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue Antimicrob. Agents Chemother. 2009, 53, 1290-1292 10.1128/AAC.01393-08
19. Mdluli, K.; Kaneko, T.; Upton, A. The tuberculosis drug discovery and development pipeline and emerging drug targets. Cold Spring Harb Cold Spring Harbor Perspect. Med. 2015, 5, a021154 10.1101/cshperspect.a021154
20. von Ballmoos, C.; Cook, G. M.; Dimroth, P. Unique rotary ATP synthase and its biological diversity Annu. Rev. Biophys. 2008, 37, 43-64 10.1146/annurev.biophys.37.032807.130018
21. Hong, S.; Pedersen, P. L. ATP Synthase and the actions of inhibitors utilized to study its roles in human health, disease, and other scientific areas Microbiol. Mol. biol. Rev. 2008, 72, 590-641 10.1128/MMBR.00016-08
22. Beechey, R. B.; Holloway, C. T.; Knight, I. G.; Roberton, A. M. Dicyclohexylcarbodiimide-An inhibitor of oxidative phosphorylation Biochem. Biophys. Res. Commun. 1966, 23, 75-80 10.1016/0006-291X(66)90271-3
23. Matsuno-Yagi, A.; Hatefi, Y. Studies on the mechanism of oxidative phosphorylation. ATP synthesis by submitochondrial particles inhibited at Fo by venturicidin and organotin compounds J. Biol. Chem. 1993a, 268, 6186-6173
24. Matsuno-Yagi, A.; Hatefi, Y. Studies on the mechanism of oxidative phosphorylation. Different effects of Fo inhibitors on unisite and multisite ATP hydrolysis by bovine submitochondrial particles J. Biol. Chem. 1993b, 268, 1539-1545
25. Amacher, D. E. Drug-associated mitochondrial toxicity and its detection Curr. Med. Chem. 2005, 12, 1829-1839 10.2174/0929867054546663
26. Wallace, K. B.; Starkov, A. A. Mitochondrial targets of drug toxicity Annu. Rev. Pharmacol. Toxicol. 2000, 40, 353-388 10.1146/annurev.pharmtox.40.1.353
27. Koul, A.; Vranckx, L.; Dendouga, N.; Balemans, W.; van den Wyngaert, I.; Vergauwen, K.; Göhlmann, H. W. H.; Willebrords, R.; Poncelet, A.; Guillemont, J.; Bald, D.; Andries, K. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis J. Biol. Chem. 2008, 283, 25273-25280 10.1074/jbc.M803899200
28. Lounis, N.; Veziris, N.; Chauffour, A.; Truffot-Pernot, C.; Andries, K.; Jarlier, V. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration Antimicrob. Agents Chemother. 2006, 50, 3543-3547 10.1128/AAC.00766-06
29. Ibrahim, M.; Andries, K.; Lounis, N.; Chauffour, A.; Truffot-Pernot, C.; Jarlier, V.; Veziris, N. Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis Antimicrob. Agents Chemother. 2007, 51, 1011-1015 10.1128/AAC.00898-06
30. F.D.A. Approves Drug for Resistant Tuberculosis. New York Times, December 31, 2012; http://www.nytimes.com/2013/01/01/business/fda-approves-new-tuberculosis-drug.html?_r=1&.
31. Mak, P. A.; Rao, S. P. S.; Tan, M. P.; Lin, X.; Chyba, J.; Tay, J.; Ng, S. H.; Tan, B. H.; Cherian, J.; Duraiswamy, J.; Bifani, P.; Lim, V.; Lee, B. H.; Ma, N. L.; Beer, D.; Thayalan, P.; Kuhen, K.; Chatterjee, A.; Supek, F.; Glynne, R.; Zheng, J.; Boshoff, H. I.; Barry, C. E., III; Dick, T.; Pethe, K.; Camacho, L. R. A high-throughput screen to identify inhibitors of ATP homeostasis in non-replicating Mycobacterium tuberculosis ACS Chem. Biol. 2012, 7, 1190-1197 10.1021/cb2004884
32. Abrahams, K. A.; Cox, J. A. G.; Spivey, V. L.; Loman, N. J.; Pallen, M. J.; Constantinidou, C.; Fernández, R.; Alemparte, C.; Remuiñán, M. J.; Barros, D.; Ballell, L.; Besra, G. S. Identification of novel imidazo[1,2-a]pyridine inhibitors targeting M. tuberculosis QcrB PLoS One 2012, 7, e52951 10.1371/journal.pone.0052951
33. Pethe, K.; Bifani, P.; Jang, J.; Kang, S.; Park, S.; Ahn, S.; Jiricek, J.; Jung, J.; Jeon, H. K.; Cechetto, J.; Christophe, T.; Lee, H.; Kempf, M.; Jackson, M.; Lenaerts, A. J.; Pham, H.; Jones, V.; Seo, M. J.; Kim, Y. M.; Seo, M.; Seo, J. J.; Park, D.; Ko, Y.; Choi, I.; Kim, R.; Kim, S. Y.; Lim, S.; Yim, S. A.; Nam, J.; Kang, H.; Kwon, H.; Oh, C. T.; Cho, Y.; Jang, Y.; Kim, J.; Chua, A.; Tan, B. H.; Nanjundappa, M. B.; Rao, S. P.; Barnes, W. S.; Wintjens, R.; Walker, J. R.; Alonso, S.; Lee, S.; Kim, J.; Oh, S.; Oh, T.; Nehrbass, U.; Han, S. J.; No, Z.; Lee, J.; Brodin, P.; Cho, S. N.; Nam, K.; Kim, J. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis Nat. Med. 2013, 19, 1157-1160 10.1038/nm.3262
34. Khan, S. R.; Singh, S.; Roy, K. K.; Akhtar, M. S.; Saxena, A. K.; Krishnan, M. Y. Biological evaluation of novel substituted chloroquinolines targeting mycobacterial ATP synthase Int. J. Antimicrob. Agents 2013, 41, 41-46 10.1016/j.ijantimicag.2012.09.012
35. Arora, K.; Ochoa-Montaño, B.; Tsang, P. S.; Blundell, T. M.; Dawes, S. S.; Mizrahi, V.; Bayliss, T.; Mackenzie, C. J.; Cleghorn, L. A. T.; Ray, P. C.; Wyatt, P. G.; Uh, E.; Lee, J.; Barry, C. E., III; Boshoff, H. I. Respiratory flexibility in response to inhibition of cytochrome c oxidase in Mycobacterium tuberculosis Antimicrob. Agents Chemother. 2014, 58, 6962-6965 10.1128/AAC.03486-14
36. Chandrasekera, N. S.; Alling, T.; Bailey, M. A.; Files, M.; Early, J. V.; Ollinger, J.; Ovechkina, Y.; Masquelin, T.; Desai, P. V.; Cramer, J. W.; Hipskind, P. A.; Odingo, J. O.; Parish, T. Identification of phenoxyalkylbenzimidazoles with antitubercular activity J. Med. Chem. 2015, 58, 7273-7285 10.1021/acs.jmedchem.5b00546
37. Tantry, S. J.; Shinde, V.; Balakrishnan, G.; Markad, S. D.; Gupta, A. K.; Bhat, J.; Narayan, A.; Raichurkar, A.; Jena, L. K.; Sharma, S.; Kumar, N.; Nanduri, R.; Bharath, S.; Reddy, J.; Panduga, V.; Prabhakar, K. R.; Kandaswamy, K.; Kaur, P.; Dinesh, N.; Guptha, S.; Saralaya, R.; Panda, M.; Rudrapatna, S.; Mallya, M.; Rubin, H.; Yano, T.; Mdluili, K.; Cooper, C. B.; Balasubramanian, V.; Sambandamurthy, V. K.; Ramachandran, V.; Shandil, R. K.; Kavanagh, S.; Narayanan, S.; Iyer, P.; Mukherjee, K.; Hosagrahara, V. K.; Solapure, S.; Hameed P, S.; Ravishankar, S. Scaffold morphing led to evolution of 2,4-diaminoquinolines and aminopyrazolopyrimidines as inhibitors of ATP synthesis pathway MedChemComm 2016, 7, 1022-1032 10.1039/C5MD00589B
38. Alcaide, B.; Plumet, J.; Sierra, M. A.; Vicent, C. Reaction of arylglyoxals with 2-amino heterocycles J. Org. Chem. 1989, 54, 5763-5768 10.1021/jo00285a024
39. Zheng, J.; Ramirez, V. D. Inhibition of mitochondrial proton FoF1-ATPase/ATP synthase by polyphenolic phytochemicals Br. J. Pharmacol. 2000, 130, 1115-1123 10.1038/sj.bjp.0703397
40. Koul, A.; Dendouga, N.; Vergauwen, K.; Molenberghs, B.; Vranckx, L.; Willebrords, R.; Ristic, Z.; Lill, H.; Dorange, I.; Guillemont, J.; Bald, D.; Andries, K. Diarylquinolines target subunit c of mycobacterial ATP synthase Nat. Chem. Biol. 2007, 3, 323-324 10.1038/nchembio884
41. Yano, T.; Kassovska-Bratinova, S.; Teh, J. S.; Winkler, J.; Sullivan, K.; Isaacs, A.; Schechter, N. M.; Rubin, H. Reduction of clofazamine by mycobacterial type 2 NADH: quinone oxidoreductase J. Biol. Chem. 2011, 286, 10276-10287 10.1074/jbc.M110.200501
42. Hille, C.; Berg, M.; Bressel, L.; Munzke, D.; Primus, P.; Löhmannsröben, H. G.; Dosche, C. Time-domain fluorescence lifetime imaging for intracellular pH sensing in living tissues Anal. Bioanal. Chem. 2008, 391, 1871-1879 10.1007/s00216-008-2147-0
43. Gentry, D. R.; Wilding, I.; Johnson, J. M.; Chen, D.; Remlinger, K.; Richards, C.; Neill, S.; Zalacain, M.; Rittenhouse, S. F.; Gwynn, M. N. A rapid microtiter plate assay for measuring the effect of compounds on Staphylococcus aureus membrane potential J. Microbiol. Methods 2010, 83, 254-256 10.1016/j.mimet.2010.08.012
44. Segala, E.; Sougakoff, W.; Nevejans-Chauffour, A.; Jarlier, V.; Petrella, S. New mutations in the mycobacterial ATP synthase: New insights into the binding of the diarylquinoline TMC207 to the ATP synthase C-ring structure Antimicrob. Agents Chemother. 2012, 56, 2326-2334 10.1128/AAC.06154-11
45. Huitric, E.; Verhasselt, P.; Koul, A.; Andries, K.; Hoffner, S.; Andersson, D. I. Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor Antimicrob. Agents Chemother. 2010, 54, 1022-1028 10.1128/AAC.01611-09
46. Preiss, L.; Langer, J. D.; Yildiz, Ö.; Eckhardt-Strelau, L.; Guillemont, J. E.; Koul, A.; Meier, T. Structure of the mycobacterial ATP synthase Fo rotor ring in complex with the anti-TB drug bedaquiline Sci. Adv. 2015, 1, e1500106 10.1126/sciadv.1500106
47. Schrödinger Suite 2013-1, Induced Fit Docking Protocol; Glide version 5.9; Prime version 3.2, Schrödinger LLC, New York, 2013.
48. Schrödinger, version 9.4; Schrodinger LLC: New York, 2013.
49. Payne, D. J.; Gwynn, M. N.; Holmes, D. J.; Pompliano, D. L. Drugs for bad bugs: Confronting the challenges of antibacterial discovery Nat. Rev. Drug Discovery 2007, 6, 29-40 10.1038/nrd2201
50. Balasubramanian, V.; Solapure, S.; Iyer, H.; Ghosh, A.; Sharma, S.; Kaur, P.; Deepthi, R.; Subbulakshmi, V.; Ramya, V.; Ramachandran, V.; Balganesh, M.; Wright, L.; Melnick, D.; Butler, S. L.; Sambandamurthy, V. K. Bactericidal activity and mechanism of action of AZD5847, a novel oxazolidinone for treatment of tuberculosis Antimicrob. Agents Chemother. 2014, 58, 495-502 10.1128/AAC.01903-13
51. Shirude, P. S.; Shandil, R.; Sadler, C.; Naik, M.; Hosagrahara, V.; Hameed, S.; Shinde, V.; Bathula, C.; Humnabadkar, V.; Kumar, N.; Reddy, J.; Panduga, V.; Sharma, S.; Ambady, A.; Hegde, N.; Whiteaker, J.; McLaughlin, R. E.; Gardner, H.; Madhavapeddi, P.; Ramachandran, V.; Kaur, P.; Narayan, A.; Guptha, S.; Awasthy, D.; Narayan, C.; Mahadevaswamy, J.; Vishwas, K. G.; Ahuja, V.; Srivastava, A.; Prabhakar, K. R.; Bharath, S.; Kale, R.; Ramaiah, M.; Choudhury, N. R.; Sambandamurthy, V. K.; Solapure, S.; Iyer, P. S.; Narayanan, S.; Chatterji, M. Azaindoles: Noncovalent DprE1 inhibitors from scaffold morphing efforts kill Mycobacterium tuberculosis and are efficacious in vivo J. Med. Chem. 2013, 56, 9701-9708 10.1021/jm401382v